Truist raised the firm’s price target on Seagen (SGEN) to $229 from $152 and keeps a Hold rating on the shares. The analyst states that the current take-over by Pfizer (PFE) should have a higher likelihood of success than last year’s efforts, and while the deal will face scrutiny by the FTC, it should "ultimately pass muster".
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SGEN:
- Seagen downgraded to Equal Weight from Overweight at Morgan Stanley
- JPMorgan biotech/pharma analysts to hold analyst/industry conference call
- Seagen price target raised to $229 from $155 at RBC Capital
- Seagen price target raised to $229 from $141 at SVB Securities
- Seagen price target raised to $229 from $210 at Oppenheimer